

DAFTAR PUSTAKA

- Ahmed, N. and Stenvers, K., 2013. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. *Frontiers in oncology*, 3, p.256.
- Alspach, E., Lussier, D.M. and Schreiber, R.D., 2018. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. *Cold Spring Harbor perspectives in biology*, p.a028480.
- Altman, A.D., Nelson, G., Chu, P., Nation, J. and Ghatage, P., 2012. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. *Journal of Obstetrics and Gynaecology Canada*, 34(6), pp.558-566.
- American Cancer Society 2018, Key Statistics for Ovarian Cancer, Atlanta: American Cancer Society, Inc. 2018, viewed 21 April 2018, <https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html>
- Anuradha, S., Webb, P.M., Blomfield, P., Brand, A.H., Friedlander, M., Leung, Y., Obermair, A., Oehler, M.K., Quinn, M., Steer, C. and Jordan, S.J., 2014. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. *Medical Journal of Australia*, 201(5), pp.283-288.
- Bouchard-Fortier, G., Panzarella, T., Rosen, B., Chapman, W. and Gien, L.T., 2017. Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow-up. *Journal of Obstetrics and Gynaecology Canada*, 39(1), pp.34-41.
- Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L. and Cheng, W.F., 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PloS one*, 13(3), p.e0194993.
- Chen, C., Chang, Y.C., Lan, M.S. and Breslin, M., 2013. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Corrigendum in/10.3892/ijo. 2016.3564. *International journal of oncology*, 42(3), pp.1113-1119.
- Chen, Y.L., Cheng, W.F., Chang, M.C., Lin, H.W., Huang, C.T., Chien, C.L. and Chen, C.A., 2013. Interferon gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. *Gynecologic oncology*, 131(1), pp.63-68.
- Chung, Y.S., Lee, J.Y., Kim, H.S., Nam, E.J., Kim, S.W. and Kim, Y.T., 2018. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. *Yonsei medical journal*, 59(8), pp.930-936.
- Cuylan, Z.F., Karabuk, E., Murat, O.Z., Turan, A.T., Meydanli, M.M., Taskin, S., Sari, M.E., Sahin, H., Ulukent, S.C., Akbayir, O. and Gungorduk, K., 2018. Comparison of stage III mucinous and serous ovarian cancer: a case-control study. *Journal of ovarian research*, 11(1), p.91.

- Ezzati, M., Abdullah, A., Shariftabrizi, A., Hou, J., Kopf, M., Stedman, J.K., Samuelson, R. and Shahabi, S., 2014. Recent advancements in prognostic factors of epithelial ovarian carcinoma. *International scholarly research notices*, 2014.
- Hosono, S., Kajiyama, H., Mizuno, K., Sakakibara, K., Matsuzawa, K., Takeda, A., Kawai, M., Nagasaka, T. and Kikkawa, F., 2011. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery. *International journal of clinical oncology*, 16(5), p.524.
- Jayson, G.C., Kohn, E.C., Kitchener, H.C. and Ledermann, J.A., 2014. Ovarian cancer. *The Lancet*, 384(9951), pp.1376-1388.
- Kim, S., Kim, B. and Song, Y.S., 2016. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. *Cancer science*, 107(9), pp.1173-1178.
- Kipps, E., Tan, D.S. and Kaye, S.B., 2013. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. *Nature Reviews Cancer*, 13(4), p.273.
- Klar, M., Hasenburg, A., Hasanov, M., Hilpert, F., Meier, W., Pfisterer, J., Pujade-Lauraine, E., Herrstedt, J., Reuss, A. and du Bois, A., 2016. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. *European Journal of Cancer*, 66, pp.114-124.
- Ku, F.C., Wu, R.C., Yang, L.Y., Tang, Y.H., Chang, W.Y., Yang, J.E., Wang, C.C., Jung, S.M., Lin, C.T., Chang, T.C. and Chao, A., 2018. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study. *Journal of the Formosan Medical Association*, 117(2), pp.117-125.
- Lazarov, N., Lazarov, L. and Lazarov, S., 2013. Age based prognosis for early epithelial ovarian cancer. *Trakia Journal of Sciences*, 11(4), p.352.
- Lee, J.Y., Kim, S., Kim, Y.T., Lim, M.C., Lee, B., Jung, K.W., Kim, J.W., Park, S.Y. and Won, Y.J., 2018. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. *BMC cancer*, 18(1), p.601.
- Mardiah, A. and Lubis, N.D., 2015. 35 Vol. 24 No. 1 Januari 2015 Ekspresi IFN- γ dan IL-4 pada Tumor Jinak dan Ganas Epitelial Ovarium Jenis Serosum dan Musinosum. *Majalah Patologi Indonesia*, 24(1).
- Marth, C., Fiegl, H., Zeimet, A.G., Müller-Holzner, E., Deibl, M., Doppler, W. and Daxenbichler, G., 2004. Interferon- γ expression is an independent prognostic factor in ovarian cancer. *American journal of obstetrics and gynecology*, 191(5), pp.1598-1605.
- Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S. and Sehouli, J., 2016. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. *Archives of gynecology and obstetrics*, 293(4), pp.695-700.
- Mizuno, M., Kajiyama, H., Shibata, K., Mizuno, K., Kawai, M., Nagasaka, T. and Kikkawa, F., 2015. Prognostic value of histological type in stage IV ovarian

- carcinoma: a retrospective analysis of 223 patients. *British journal of cancer*, 112(8), p.1376.
- Mojic, M., Takeda, K. and Hayakawa, Y., 2017. The dark side of IFN- γ : its role in promoting cancer immunoevasion. *International journal of molecular sciences*, 19(1), p.89.
- Tufan, Ö.G.E., Özalp, S.S. and Yalçın, Ö.T., 2011. Prognostic Factors In Epithelial Ovarian Carcinoma: A Reference Institution Experience. *Journal of Turkish Society of Obstetrics and Gynecology*, 8(1), pp.51-6.
- Reid, B.M., Permuth, J.B. and Sellers, T.A., 2017. Epidemiology of ovarian cancer: a review. *Cancer biology & medicine*, 14(1), p.9.
- Ricci, F., Affatato, R., Carrassa, L. and Damia, G., 2018. Recent insights into mucinous ovarian carcinoma. *International journal of molecular sciences*, 19(6), p.1569.
- Rosen, D.G., Yang, G., Liu, G., Mercado-Urbe, I., Chang, B., Xiao, X.S., Zheng, J., Xue, F.X. and Liu, J., 2009. Ovarian cancer: pathology, biology, and disease models. *Frontiers in bioscience: a journal and virtual library*, 14, p.2089.
- Sangisetty, S.L. and Miner, T.J., 2012. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. *World journal of gastrointestinal surgery*, 4(4), p.87.
- Tan, D.S. and Kaye, S., 2007. Ovarian clear cell adenocarcinoma: a continuing enigma. *Journal of clinical pathology*, 60(4), pp.355-360.
- Tang, H., Liu, Y., Wang, X., Guan, L., Chen, W., Jiang, H. and Lu, Y., 2018. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort. *Medicine*, 97(21), p.e10881.
- Trihandini, I. and Nurrika, D., 2010. Analisis ketahanan hidup lima tahun penderita kanker ovarium epithelial di Rumah Sakit Kanker Dharmas Jakarta. *Kesmas: National Public Health Journal*, 5(3), pp.139-144.
- Wall, L., Burke, F., Barton, C., Smyth, J. and Balkwill, F., 2003. IFN- γ induces apoptosis in ovarian cancer cells in vivo and in vitro. *Clinical Cancer Research*, 9(7), pp.2487-2496.
- Windbichler, G.H., Hausmaninger, H., Stummvoll, W., Graf, A.H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E. and Marth, C., 2000. Interferon gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. *British journal of cancer*, 82(6), p.1138.
- Winter, W.E., Maxwell, G.L., Tian, C., Carlson, J.W., Ozols, R.F., Rose, P.G., Markman, M., Armstrong, D.K., Muggia, F. and McGuire, W.P., 2007. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. *Journal of Clinical Oncology*, 25(24), pp.3621-3627.
- World Health Organization, 2014. WHO Classification of Tumors of Female Reproductive Organs. 4th Edition, p.15-40.
- Yoshikawa, K., Fukuda, T., Uemura, R., Matsubara, H., Wada, T., Kawanishi, M., Tasaka, R., Kasai, M., Hashiguchi, Y., Ichimura, T. and Yasui, T., 2018. Age-related differences in prognosis and prognostic factors among patients



with epithelial ovarian cancer. *Molecular and clinical oncology*, 9(3), pp.329-334.

Zhou, J., Wu, S.G., Wang, J., Sun, J.Y., He, Z.Y., Jia, X. and Zhang, W.W., 2018. The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer. *Frontiers in oncology*, 8, p.577.